FY2027 Earnings Forecast for Omeros Issued By HC Wainwright

Omeros Corporation (NASDAQ:OMER) – Equities research analysts at HC Wainwright decreased their FY2027 earnings per share (EPS) estimates for Omeros in a research report issued to clients and investors on Friday, June 26th. HC Wainwright analyst B. Folkes now forecasts that the biopharmaceutical company will earn $0.07 per share for the year, down from their prior forecast of $0.32. HC Wainwright currently has a “Buy” rating and a $33.00 target price on the stock. The consensus estimate for Omeros’ current full-year earnings is ($0.94) per share. HC Wainwright also issued estimates for Omeros’ FY2028 earnings at $2.14 EPS, FY2029 earnings at $3.95 EPS and FY2030 earnings at $5.00 EPS.

Omeros (NASDAQ:OMER) last announced its quarterly earnings data on Wednesday, May 13th. The biopharmaceutical company reported ($0.24) EPS for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.16. The company had revenue of $9.89 million for the quarter, compared to analysts’ expectations of $4.19 million.

Other research analysts have also recently issued research reports about the stock. Wall Street Zen cut shares of Omeros from a “buy” rating to a “hold” rating in a research report on Sunday, June 7th. Zacks Research upgraded shares of Omeros from a “hold” rating to a “strong-buy” rating in a research report on Thursday, April 2nd. Weiss Ratings downgraded shares of Omeros from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Tuesday, June 2nd. Finally, D. Boral Capital reiterated a “buy” rating and issued a $36.00 target price on shares of Omeros in a report on Tuesday, April 21st. Two analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $38.00.

Omeros Stock Up 14.3%

Shares of NASDAQ:OMER opened at $9.91 on Tuesday. Omeros has a 52-week low of $2.95 and a 52-week high of $17.65. The stock has a market cap of $717.24 million, a P/E ratio of 14.16 and a beta of 2.52. The business has a fifty day moving average of $11.84 and a two-hundred day moving average of $11.85.

Insider Activity

In related news, Director Thomas J. Cable sold 7,500 shares of the firm’s stock in a transaction dated Friday, May 22nd. The stock was sold at an average price of $11.61, for a total transaction of $87,075.00. Following the completion of the sale, the director directly owned 35,067 shares of the company’s stock, valued at approximately $407,127.87. This trade represents a 17.62% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 10.50% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of OMER. State of Wyoming purchased a new stake in shares of Omeros in the 4th quarter valued at approximately $25,000. Caitong International Asset Management Co. Ltd purchased a new position in shares of Omeros during the 4th quarter worth approximately $33,000. Assetmark Inc. purchased a new position in shares of Omeros during the 1st quarter worth approximately $38,000. Arax Advisory Partners increased its holdings in Omeros by 56.4% in the 4th quarter. Arax Advisory Partners now owns 5,255 shares of the biopharmaceutical company’s stock valued at $90,000 after purchasing an additional 1,894 shares during the last quarter. Finally, International Assets Investment Management LLC increased its holdings in Omeros by 16.0% in the 1st quarter. International Assets Investment Management LLC now owns 5,800 shares of the biopharmaceutical company’s stock valued at $61,000 after purchasing an additional 800 shares during the last quarter. Hedge funds and other institutional investors own 48.79% of the company’s stock.

About Omeros

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.